Promising drug combo for Hard-to-Treat breast cancer falls short in early trial
NCT ID NCT03289039
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug neratinib, alone or with fulvestrant, in 21 people with HER2-positive, ER-positive metastatic breast cancer. The study aimed to see if the combination could slow cancer growth. However, the trial was terminated early, meaning we have limited data on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Neratinib (a pill that blocks HER2 protein) and Fulvestrant (a hormone therapy injection)
What this could lead to
If successful, this could point toward a new treatment option for people with HER2-positive, ER-positive metastatic breast cancer.
What could go wrong
This was a small, early-phase trial that was terminated early, so results are limited. The drug may not work better than existing treatments and can cause side effects like diarrhea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, 03053, United States
-
Eastern Maine Medical Center
Brewer, Maine, 04412, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
UT Southwestern
Dallas, Texas, 75390, United States